SCHEMBL3438840

SCHEMBL3438840

CC(C)(C)OC(=O)N1CCC2(C=Cc3ccc(Br)cc32)CC1

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.41
TSHR P16473 2/20 0.39
BACE1 P56817 1/20 0.39
RORC P51449 1/20 0.39
ALOX15 P16050 1/20 0.39
ATM Q13315 1/20 0.39
ESR2 Q92731 1/20 0.39
FPR3 P25089 1/20 0.39
FPR2 P25090 1/20 0.39
USP30 Q70CQ3 1/20 0.39
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30508294 0.91 GPR119 (0.41) GPR119TSHRBACE1RORCALOX15
SCHEMBL22471455 0.91 GPR119 (0.41) GPR119TSHRBACE1RORCALOX15
SCHEMBL4917650 0.86 HSD11B1 (0.47) TSHRALOX15ATMESR2
SCHEMBL3438841 0.84 HDAC1 (0.38) GPR119TSHRALOX15ATMESR2
SCHEMBL30107924 0.83 HSD11B1 (0.54) TSHRALOX15ATM
SCHEMBL1577665 0.83 HSD11B1 (0.54) TSHRALOX15ATM
SCHEMBL1785500 0.79 HSD11B1 (0.47) TSHRALOX15ATMESR2
SCHEMBL1785499 0.79 HSD11B1 (0.47) TSHRALOX15ATMESR2
SCHEMBL34460287 0.79 HTR2C (0.52) GPR119BACE1RORCFPR3FPR2
SCHEMBL3717760 0.78 GPR119 (0.43) GPR119TSHRBACE1RORCALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3950682-B1 PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) 2026-02-11 EP disclosed
US-20260008760-A1 DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF INSMED INCORPORATED 2026-01-08 US disclosed
US-12473298-B2 Amide compounds, preparation method therefor, and use thereof in the medical field SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) 2025-11-18 US disclosed
US-12466829-B2 Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2025-11-11 US disclosed
US-20230126662-A1 SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-04-27 US disclosed
EP-3950682-A1 PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) 2022-02-09 EP disclosed
WO-2021133563-A1 SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2021-07-01 WO disclosed
US-8536189-B2 Spiropiperidines for use as tryptase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-09-17 US disclosed
US-20120165327-A1 SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS COSTANZO MICHAEL J (US) 2012-06-28 US disclosed
US-8158792-B2 Spiropiperidines for use as tryptase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2012-04-17 US disclosed
US-8158792-B2 Spiropiperidines for use as tryptase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2012-04-17 US disclosed
US-20090163527-A1 Spiropiperidines for use as tryptase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2009-06-25 US disclosed
US-20090163527-A1 Spiropiperidines for use as tryptase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2009-06-25 US disclosed
WO-2009067202-A1 SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466829-B2 Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC2R, MC1R, MC3R GPR119 93/4885TSHR 102/4885BACE1 4444/4885
US-12473298-B2 Amide compounds, preparation method therefor, and use thereof in the medical field EZH2, IKZF2, EZH1 GPR119 2804/4885TSHR 2569/4885BACE1 3988/4885
US-20120165327-A1 SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS TPSAB1, TPSB2, TPSD1 GPR119 797/4885TSHR 654/4885BACE1 1743/4885
US-20090163527-A1 Spiropiperidines for use as tryptase inhibitors TPSAB1, TPSB2, TPSD1 GPR119 797/4885TSHR 654/4885BACE1 1743/4885
US-20260008760-A1 DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF DPP9, DPP7, DPP4 GPR119 127/4885TSHR 1159/4885BACE1 268/4885
US-20230126662-A1 SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC2R, MC1R, MC3R GPR119 93/4885TSHR 102/4885BACE1 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.